RHOVAC Stock Overview
RhoVac AB, a pharmaceutical company, develops and commercializes drugs for the treatment of cancer in Sweden and Denmark. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
RhoVac AB Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 1.16 |
52 Week High | SEK 38.00 |
52 Week Low | SEK 0.47 |
Beta | 1.17 |
1 Month Change | 8.61% |
3 Month Change | 96.61% |
1 Year Change | -95.72% |
3 Year Change | -91.45% |
5 Year Change | -92.75% |
Change since IPO | -91.62% |
Recent News & Updates
Recent updates
Shareholder Returns
RHOVAC | SE Biotechs | SE Market | |
---|---|---|---|
7D | -17.5% | 3.4% | 1.9% |
1Y | -95.7% | 16.9% | 7.6% |
Return vs Industry: RHOVAC underperformed the Swedish Biotechs industry which returned -2.8% over the past year.
Return vs Market: RHOVAC underperformed the Swedish Market which returned 5.8% over the past year.
Price Volatility
RHOVAC volatility | |
---|---|
RHOVAC Average Weekly Movement | 38.5% |
Biotechs Industry Average Movement | 8.9% |
Market Average Movement | 5.6% |
10% most volatile stocks in SE Market | 11.4% |
10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: RHOVAC's share price has been volatile over the past 3 months.
Volatility Over Time: RHOVAC's weekly volatility has increased from 27% to 38% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | n/a | Lars Hedbys | www.rhovac.com |
RhoVac AB, a pharmaceutical company, develops and commercializes drugs for the treatment of cancer in Sweden and Denmark. Its primary product candidate is RV001, an immuno-oncologic drug, which is in phase IIb clinical phase to identify and destroy cells that carry metastatic or metastatic potential cells. The company was founded in 2007 and is headquartered in Lund, Sweden.
RhoVac AB Fundamentals Summary
RHOVAC fundamental statistics | |
---|---|
Market cap | SEK 22.09m |
Earnings (TTM) | -SEK 50.33m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs RHOVAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RHOVAC income statement (TTM) | |
---|---|
Revenue | SEK 0 |
Cost of Revenue | SEK 0 |
Gross Profit | SEK 0 |
Other Expenses | SEK 50.34m |
Earnings | -SEK 50.33m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 27, 2023
Earnings per share (EPS) | -2.64 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did RHOVAC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2023/01/18 05:04 |
End of Day Share Price | 2023/01/18 00:00 |
Earnings | 2022/09/30 |
Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RhoVac AB is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Jonas Peciulis | Edison Investment Research |